Importantly, our studies have shown that in the experimental murine melanoma model, host PAFR activation can augment the growth of tumor xenografts or impede the anti-tumoral immune response of therapeutic agents via mechanisms involving COX-2-dependent upregulation of Tregs [30,31,56]. This evidence concerns the gene PTAFR and neoplasm.